Abstract 687TiP
Background
Delta-like 1 homolog protein (DLK1), also known as preadipocyte factor 1 (PREF-1) and fetal antigen 1 (FA1), is a transmembrane protein and an inhibitor of NOTCH1 signaling. It modulates a wide range of developmental processes where NOTCH signaling is critical including cellular proliferation, cell fate, and terminal differentiation. As a result of its role in developmental signaling, expression of DLK1 decreases as development proceeds, with limited expression in adult tissues, with the exception of adrenal and pituitary glands, and ovaries. DLK1 is highly expressed in several cancers, including adrenocortical, uterine, and testicular cancers as well as a subset of pancreatic, sarcoma, liver, and lung cancers. Taken together, this expression profile makes DLK1 an attractive candidate for targeted therapeutic approaches. TORL-4-500 is an antibody-drug conjugate (ADC) with a fully humanized immunoglobulin G1 (IgG1) monoclonal antibody (mAb) selective for DLK1 linked to monomethyl auristatin E (MMAE), an anti-mitotic agent via a cathepsin hydrolysable dipeptide valine-citrulline (vc) linker.
Trial design
TORL-4-500-001 is a two-part first in human study to characterize the safety, tolerability, and dose-limiting toxicities (DLT) and to determine the maximum tolerated dose (MTD) and recommended phase 2 dose (RP2D) of TORL-4-500 administered as monotherapy intravenously Q3W in patients with advanced cancer. Serum PK, immunogenicity, and antitumor activity will also be evaluated. Endpoints include frequency and severity of adverse events and objective response rate (ORR) based on RECIST v1.1 criteria. Correlative biomarker studies will evaluate the relationship of clinical benefit with blood and tissue biomarkers. This study is currently open with patients enrolling in dose escalation. Once the RP2D is established, dose expansion in DLK1+ indication-specific cohorts will commence.
Clinical trial identification
NCT06005740.
Editorial acknowledgement
Legal entity responsible for the study
TORL Biotherapeutics.
Funding
TORL Biotherapeutics.
Disclosure
J.W. Goldman: Financial Interests, Personal, Invited Speaker: AstraZeneca; Financial Interests, Personal, Advisory Board: Genentech, Eli Lilly, Janssen, AbbVie, Gritstone; Financial Interests, Institutional, Coordinating PI: AstraZeneca, Eli Lilly; Financial Interests, Institutional, Local PI: Genentech, Janssen, BMS, AbbVie. L.S. Rosen: Financial Interests, Institutional, Funding, PI at UCLA Health Hem/Onc for Inspirna trial, Institution receives research funding: Inspirna. A. Kung, A. Romero, I. Qazi, H. Dokainish, S. Letrent: Financial Interests, Personal, Stocks/Shares: TORL Bio. D. Slamon: Financial Interests, Personal and Institutional, Member of Board of Directors: TORL Bio.
Resources from the same session
621P - Phase II trial of encorafenib and binimetinib (E+B) in patients (pts) with BRAF-altered advanced solid tumors: Results of E+B cohort in the BELIEVE trial (NCCH1901)
Presenter: Yoshitaka Honma
Session: Poster session 01
622P - Safety and efficacy of ifebemtinib (IN10018) combined with D-1553 in solid tumors with KRAS G12C mutation: Results from a phase Ib/II study
Presenter: Zhengbo Song
Session: Poster session 01
624P - Belvarafenib in patients (pts) with BRAF class II or III alteration-positive tumours: TAPISTRY study
Presenter: Rafal Dziadziuszko
Session: Poster session 01
625P - Initial results from the phase I, first-in-human study of the covalent, PI3Kα inhibitor TOS-358 in patients with solid tumors, expressing PI3Kα mutations or amplifications
Presenter: Marwan Fakih
Session: Poster session 01
626P - Roginolisib (IOA-244), a first oral allosteric modulator of phosphoinositide 3-kinase inhibitor delta (PI3Kδ) in patients with metastatic uveal melanoma
Presenter: Anna Di Giacomo
Session: Poster session 01
627P - Long-term efficacy and safety of larotrectinib in non-primary central nervous system (CNS) TRK fusion cancer
Presenter: Alexander Drilon
Session: Poster session 01
628P - Efficacy and safety of larotrectinib as first-line treatment for patients (pts) with TRK fusion cancer: An updated analysis
Presenter: David Hong
Session: Poster session 01
629P - Phase I study of pamiparib and cabozantinib in patients with metastatic solid tumors harboring homologous recombination deficiency (HRD)
Presenter: Siqing Fu
Session: Poster session 01